Related Experiment Video
Updated: May 29, 2026

09:47
DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
Published on: December 15, 2023
Longitudinal Feature Disentanglement With Cross-Time Contrastive Learning for Alzheimer's Disease Diagnosis
IEEE Journal of Biomedical and Health Informatics
|May 27, 2026
Summary
This study introduces a new AI network to analyze brain changes over time, improving Alzheimer's disease diagnosis and predicting disease progression using brain scans.
Area of Science:
- Neuroimaging
- Artificial Intelligence
- Medical Diagnostics
Background:
- Longitudinal structural MRI is crucial for tracking brain atrophy in Alzheimer's Disease (AD).
- Analyzing longitudinal data is complex due to inter-temporal correlations, noise, and redundancy.
- Existing methods struggle to effectively model these dynamic changes for accurate AD progression prediction.
Purpose of the Study:
- To develop a novel deep learning model for enhanced Alzheimer's Disease diagnosis and progression prediction.
- To address the challenges of modeling complex temporal dynamics and noise in longitudinal brain imaging data.
- To disentangle stable, disease-specific features from variable, noise-related features in brain scans.
Main Methods:
- Proposed a Longitudinal Feature Disentanglement Network using a 3D convolutional encoder with weight sharing.
- Employed a Variational Autoencoder (VAE) to disentangle spatial representations into stable and marginal features.
- Incorporated cross-time-point contrastive learning and a longitudinal feature reconstruction module.
Main Results:
- The proposed network achieved superior performance in Alzheimer's Disease diagnosis compared to state-of-the-art methods.
- Demonstrated high accuracy in predicting Mild Cognitive Impairment (MCI) to AD conversion.
- Visualization analysis confirmed the model's ability to identify key brain regions and interpret its decisions.
Conclusions:
- The Longitudinal Feature Disentanglement Network effectively analyzes longitudinal sMRI data for AD.
- The method shows significant potential for improving early diagnosis and predicting AD progression.
- This approach offers a robust framework for leveraging complex neuroimaging data in AD research.
Related Concept Videos
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...